Related Experiment Video
Updated: Aug 8, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review.
Casper Steenholdt1, Pernille Dige Ovesen1, Jørn Brynskov1
1Department of Gastroenterology, Herlev Hospital, Herlev, Denmark.
Journal of Crohn'S & Colitis
|March 2, 2023
Summary
Tofacitinib shows promise for treating acute severe ulcerative colitis (ASUC), offering high short-term colectomy-free survival in refractory patients. Further high-quality research is necessary to confirm these findings.
Area of Science:
- Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Acute severe ulcerative colitis (ASUC) is a debilitating condition requiring effective treatment options.
- Tofacitinib is an emerging therapeutic agent for ASUC, necessitating a comprehensive review of its clinical utility.
Conclusions:
- Tofacitinib demonstrates promising efficacy in ASUC, particularly for refractory patients at high risk of colectomy.
- The drug exhibits favorable short-term colectomy-free survival rates.
- Larger, high-quality studies are required to solidify tofacitinib's role in ASUC treatment algorithms.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
208
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
208
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
226
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
226
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
263
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
263